Table of Content

1 Study Coverage
1.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Introduction
1.2 Market by Type
1.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Flow Cytometry
1.3.3 ELISA
1.3.4 Western Blot
1.3.5 Immunoprecipitation
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Estimates and Forecasts 2018-2029
2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region
2.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2018-2024)
2.2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2024-2029)
2.2.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2018-2029)
2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Estimates and Forecasts 2018-2029
2.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region
2.4.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2018-2024)
2.4.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2024-2029)
2.4.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Manufacturers
3.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Manufacturers (2018-2024)
3.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody in 2022
3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Manufacturers
3.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Manufacturers (2018-2024)
3.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue in 2022
3.3 Global Key Players of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Product Offered and Application
3.8 Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type
4.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Historical Sales by Type (2018-2024)
4.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecasted Sales by Type (2024-2029)
4.1.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2018-2029)
4.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type
4.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Historical Revenue by Type (2018-2024)
4.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecasted Revenue by Type (2024-2029)
4.2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2018-2029)
4.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Type
4.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Type (2018-2024)
4.3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application
5.1.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Historical Sales by Application (2018-2024)
5.1.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecasted Sales by Application (2024-2029)
5.1.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2018-2029)
5.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application
5.2.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Historical Revenue by Application (2018-2024)
5.2.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Forecasted Revenue by Application (2024-2029)
5.2.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application (2018-2029)
5.3 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Application
5.3.1 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Application (2018-2024)
5.3.2 Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Type
6.1.1 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2029)
6.1.2 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2029)
6.2 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Application
6.2.1 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2029)
6.2.2 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2029)
6.3 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country
6.3.1 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2018-2029)
6.3.3 US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Type
7.1.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2029)
7.1.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2029)
7.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Application
7.2.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2029)
7.2.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2029)
7.3 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Country
7.3.1 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2018-2029)
7.3.3 Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size
8.1.1 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (2018-2029)
8.1.2 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue (2018-2029)
8.2 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Application
8.2.1 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2029)
8.2.2 China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Type
9.1.1 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2029)
9.1.2 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2029)
9.2 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Application
9.2.1 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2029)
9.2.2 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2029)
9.3 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region
9.3.1 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2018-2029)
9.3.3 Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Type
10.1.1 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size by Application
10.2.1 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country
10.3.1 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Sino Biological, Inc.
11.1.1 Sino Biological, Inc. Company Information
11.1.2 Sino Biological, Inc. Overview
11.1.3 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sino Biological, Inc. Recent Developments
11.2 LifeSpan BioSciences, Inc
11.2.1 LifeSpan BioSciences, Inc Company Information
11.2.2 LifeSpan BioSciences, Inc Overview
11.2.3 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 LifeSpan BioSciences, Inc Recent Developments
11.3 Abcam
11.3.1 Abcam Company Information
11.3.2 Abcam Overview
11.3.3 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Abcam Recent Developments
11.4 Thermo Fisher Scientific (China) Co., Ltd.
11.4.1 Thermo Fisher Scientific (China) Co., Ltd. Company Information
11.4.2 Thermo Fisher Scientific (China) Co., Ltd. Overview
11.4.3 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
11.5 Bio-Techne
11.5.1 Bio-Techne Company Information
11.5.2 Bio-Techne Overview
11.5.3 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bio-Techne Recent Developments
11.6 Boster Biological Technology
11.6.1 Boster Biological Technology Company Information
11.6.2 Boster Biological Technology Overview
11.6.3 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Boster Biological Technology Recent Developments
11.7 Merck
11.7.1 Merck Company Information
11.7.2 Merck Overview
11.7.3 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Merck Recent Developments
11.8 RayBiotech, Inc.
11.8.1 RayBiotech, Inc. Company Information
11.8.2 RayBiotech, Inc. Overview
11.8.3 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 RayBiotech, Inc. Recent Developments
11.9 Assay Genie
11.9.1 Assay Genie Company Information
11.9.2 Assay Genie Overview
11.9.3 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Assay Genie Recent Developments
11.10 Creative Biolabs
11.10.1 Creative Biolabs Company Information
11.10.2 Creative Biolabs Overview
11.10.3 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Creative Biolabs Recent Developments
11.11 MyBiosource, Inc.
11.11.1 MyBiosource, Inc. Company Information
11.11.2 MyBiosource, Inc. Overview
11.11.3 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 MyBiosource, Inc. Recent Developments
11.12 OriGene Technologies, Inc.
11.12.1 OriGene Technologies, Inc. Company Information
11.12.2 OriGene Technologies, Inc. Overview
11.12.3 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 OriGene Technologies, Inc. Recent Developments
11.13 Creative Diagnostics
11.13.1 Creative Diagnostics Company Information
11.13.2 Creative Diagnostics Overview
11.13.3 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Creative Diagnostics Recent Developments
11.14 Abbexa
11.14.1 Abbexa Company Information
11.14.2 Abbexa Overview
11.14.3 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Abbexa Recent Developments
11.15 Biorbyt
11.15.1 Biorbyt Company Information
11.15.2 Biorbyt Overview
11.15.3 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.15.4 Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Biorbyt Recent Developments
11.16 Abeomics Inc.
11.16.1 Abeomics Inc. Company Information
11.16.2 Abeomics Inc. Overview
11.16.3 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.16.4 Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Abeomics Inc. Recent Developments
11.17 CUSABIO
11.17.1 CUSABIO Company Information
11.17.2 CUSABIO Overview
11.17.3 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.17.4 CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 CUSABIO Recent Developments
11.18 Enzo Life Sciences, Inc.
11.18.1 Enzo Life Sciences, Inc. Company Information
11.18.2 Enzo Life Sciences, Inc. Overview
11.18.3 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales, Price, Revenue and Gross Margin (2018-2024)
11.18.4 Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Enzo Life Sciences, Inc. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Chain Analysis
12.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Production Mode & Process
12.4 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales and Marketing
12.4.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Channels
12.4.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors
12.5 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customers
13 Market Dynamics
13.1 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Industry Trends
13.2 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Drivers
13.3 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Challenges
13.4 Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Restraints
14 Key Findings in The Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Monoclonal Antibody
Table 3. Major Manufacturers of Polyclonal Antibody
Table 4. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2018-2024)
Table 9. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2024-2029)
Table 10. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2018-2024) & (K Units)
Table 12. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2024-2029) & (K Units)
Table 13. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2018-2024)
Table 14. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2024-2029)
Table 15. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Manufacturers (2018-2024)
Table 17. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody as of 2022)
Table 23. Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Product Offered and Application
Table 25. Global Key Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2024) & (K Units)
Table 28. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2024-2029) & (K Units)
Table 29. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Type (2018-2024)
Table 30. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Type (2024-2029)
Table 31. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Type (2018-2024)
Table 34. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Type (2024-2029)
Table 35. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2024) & (K Units)
Table 38. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2024-2029) & (K Units)
Table 39. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Application (2018-2024)
Table 40. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Share by Application (2024-2029)
Table 41. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Application (2018-2024)
Table 44. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Share by Application (2024-2029)
Table 45. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2024-2029) & (K Units)
Table 60. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2024) & (K Units)
Table 61. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2024-2029) & (K Units)
Table 62. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2024) & (K Units)
Table 65. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2024-2029) & (K Units)
Table 66. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2018-2024) & (K Units)
Table 72. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2024-2029) & (K Units)
Table 73. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2024) & (K Units)
Table 74. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2024-2029) & (K Units)
Table 75. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2024) & (K Units)
Table 78. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2024-2029) & (K Units)
Table 79. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2024) & (K Units)
Table 82. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2024-2029) & (K Units)
Table 83. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2024) & (K Units)
Table 86. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2024-2029) & (K Units)
Table 87. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2018-2024) & (K Units)
Table 93. Asia Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales by Country (2024-2029) & (K Units)
Table 107. Sino Biological, Inc. Company Information
Table 108. Sino Biological, Inc. Description and Major Businesses
Table 109. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. Sino Biological, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Sino Biological, Inc. Recent Developments
Table 112. LifeSpan BioSciences, Inc Company Information
Table 113. LifeSpan BioSciences, Inc Description and Major Businesses
Table 114. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. LifeSpan BioSciences, Inc Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. LifeSpan BioSciences, Inc Recent Developments
Table 117. Abcam Company Information
Table 118. Abcam Description and Major Businesses
Table 119. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Abcam Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Abcam Recent Developments
Table 122. Thermo Fisher Scientific (China) Co., Ltd. Company Information
Table 123. Thermo Fisher Scientific (China) Co., Ltd. Description and Major Businesses
Table 124. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Thermo Fisher Scientific (China) Co., Ltd. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Thermo Fisher Scientific (China) Co., Ltd. Recent Developments
Table 127. Bio-Techne Company Information
Table 128. Bio-Techne Description and Major Businesses
Table 129. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Bio-Techne Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Bio-Techne Recent Developments
Table 132. Boster Biological Technology Company Information
Table 133. Boster Biological Technology Description and Major Businesses
Table 134. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. Boster Biological Technology Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Boster Biological Technology Recent Developments
Table 137. Merck Company Information
Table 138. Merck Description and Major Businesses
Table 139. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Merck Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Merck Recent Developments
Table 142. RayBiotech, Inc. Company Information
Table 143. RayBiotech, Inc. Description and Major Businesses
Table 144. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. RayBiotech, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. RayBiotech, Inc. Recent Developments
Table 147. Assay Genie Company Information
Table 148. Assay Genie Description and Major Businesses
Table 149. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Assay Genie Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Assay Genie Recent Developments
Table 152. Creative Biolabs Company Information
Table 153. Creative Biolabs Description and Major Businesses
Table 154. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Creative Biolabs Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Creative Biolabs Recent Developments
Table 157. MyBiosource, Inc. Company Information
Table 158. MyBiosource, Inc. Description and Major Businesses
Table 159. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. MyBiosource, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. MyBiosource, Inc. Recent Developments
Table 162. OriGene Technologies, Inc. Company Information
Table 163. OriGene Technologies, Inc. Description and Major Businesses
Table 164. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. OriGene Technologies, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. OriGene Technologies, Inc. Recent Developments
Table 167. Creative Diagnostics Company Information
Table 168. Creative Diagnostics Description and Major Businesses
Table 169. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Creative Diagnostics Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Creative Diagnostics Recent Developments
Table 172. Abbexa Company Information
Table 173. Abbexa Description and Major Businesses
Table 174. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Abbexa Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Abbexa Recent Developments
Table 177. Biorbyt Company Information
Table 178. Biorbyt Description and Major Businesses
Table 179. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 180. Biorbyt Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 181. Biorbyt Recent Developments
Table 182. Abeomics Inc. Company Information
Table 183. Abeomics Inc. Description and Major Businesses
Table 184. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 185. Abeomics Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 186. Abeomics Inc. Recent Developments
Table 187. CUSABIO Company Information
Table 188. CUSABIO Description and Major Businesses
Table 189. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 190. CUSABIO Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 191. CUSABIO Recent Developments
Table 192. Enzo Life Sciences, Inc. Company Information
Table 193. Enzo Life Sciences, Inc. Description and Major Businesses
Table 194. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 195. Enzo Life Sciences, Inc. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Model Numbers, Pictures, Descriptions and Specifications
Table 196. Enzo Life Sciences, Inc. Recent Developments
Table 197. Key Raw Materials Lists
Table 198. Raw Materials Key Suppliers Lists
Table 199. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Distributors List
Table 200. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Customers List
Table 201. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Trends
Table 202. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Drivers
Table 203. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Challenges
Table 204. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Restraints
Table 205. Research Programs/Design for This Report
Table 206. Key Data Information from Secondary Sources
Table 207. Key Data Information from Primary Sources
List of Figures
Figure 1. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Product Picture
Figure 2. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Type in 2022 & 2029
Figure 4. Monoclonal Antibody Product Picture
Figure 5. Polyclonal Antibody Product Picture
Figure 6. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Application in 2022 & 2029
Figure 8. Flow Cytometry
Figure 9. ELISA
Figure 10. Western Blot
Figure 11. Immunoprecipitation
Figure 12. Others
Figure 13. Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Report Years Considered
Figure 14. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue 2018-2029 (US$ Million)
Figure 16. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Region (2018-2029)
Figure 18. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales 2018-2029 ((K Units)
Figure 19. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales YoY (2018-2029) & (K Units)
Figure 25. China Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody in the World: Market Share by Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue in 2022
Figure 32. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2018-2029)
Figure 34. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Type (2018-2029)
Figure 35. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Application (2018-2029)
Figure 36. Global Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Antibody Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACA